SubQuery: Business owner report
Expanded web report · Related PDF snapshot: 22 October 2026 · PDF page 16
Research reviewed 22 October 2026 · Evidence and editorial planning guidance are distinguished below.
Choose the investment and accept the residual risk
Assess the business authority attached to build environments. A low-cost dependency can sit beside credentials capable of publishing trusted software. Fund investigation of the release path and decide what independent assurance is proportionate to the products at risk.
Your immediate priorities
- Assign ownership of package publishing and emergency release approval.
- Review concentration of credentials and the ability to rebuild independently.
How to work through the decision
Compare the cost of interruption, response and sustained improvement separately. Use your actual trading volumes, staff costs and contractual commitments; this report supplies no universal loss estimate. Identify who can approve emergency spending and who can accept a temporary exception. A supplier change should have measurable acceptance criteria, retained responsibilities and an exit route, rather than an assumption that a brand eliminates risk.
Evidence to ask for
A release assurance decision with investment priorities for reducing publishing risk.
What evidence would let us confidently distribute a new version after this incident?
Work with the next person
Give the business manager a clear continuity priority, spending authority and escalation threshold. Ask for unresolved decisions and evidence gaps, not only a red, amber or green status.
Continue with the business manager report for this topic.
A scenario to rehearse
Illustrative exercise, not an observed customer incident: A package is absent from the application’s direct dependency list but appears in the CI lockfile through a build tool. The exercise follows the install path and publishing credentials rather than closing the case after a source-code search.
What a useful outcome looks like
A release assurance decision with investment priorities for reducing publishing risk. Keep the decision dated and return to it if new evidence changes the scope.